Out of stock

This item is currently unavailable

Gone for 64 days. Could come back at any time — we're watching for you.

Out of stock 64 days

World Outlook: Hormone Therapy for Prostate Cancer 2025-2030

Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

No price data yet

Price history will appear here once data is collected from Amazon.

View at Amazon ↗
Out of stock

Price data last checked 64 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

No price data available for histogram

Description
This specialized report, The 2025-2030 World Outlook for Hormone Therapy for Prostate Cancer Therapeutics, provides a detailed analysis of the market landscape. Published by ICON Group International, Inc., this book serves as a professional resource for understanding the evolving field of prostate cancer therapeutics. It covers the projected trends and outlook for hormone therapy through the year 2030, offering essential data for those studying medical market developments and therapeutic advancements in this specific sector.

Key Features

Covers the global outlook for hormone therapy for prostate cancer from 2025 to 2030.

Authored and published by ICON Group International, Inc. for professional use.

Provides detailed information on prostate cancer therapeutics and market trends.

Categorized under Books for specialized subject matter research.

Product Specifications
Format
paperback
ASIN
B0CZM1G92B
Category
Books > Subjects
Domain
Amazon UK
Release Date
03 March 2024
Listed Since
05 May 2024